Buy

Search documents
Viridian Therapeutics: The Song Remains The Same
Seeking Alpha· 2025-06-09 22:18
Group 1 - The discussion in the biotech community has focused on profitable buy-write or covered call strategies for selected biotech stocks over recent months [1] - Viridian Therapeutics, Inc. (NASDAQ: VRDN) has been highlighted as a promising clinical-stage biotech company, despite a significant stock price drop of one-third since the last analysis [2] - The investing group, The Biotech Forum, offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions and weekly market commentary [2] Group 2 - The article emphasizes that the analyst holds a beneficial long position in VRDN shares through various financial instruments [3] - There is a disclaimer regarding past performance not guaranteeing future results, and no specific investment advice is provided [4]
Science Applications International Is a Wicked Hot Buy in June
MarketBeat· 2025-06-09 19:20
Core Viewpoint - Science Applications International (SAIC) presents a compelling investment opportunity following a significant decline in share price, attributed to initial uncertainties regarding government spending, which have since been alleviated [2][8]. Financial Performance - SAIC reported net revenue of $1.88 billion for Q1 2025, marking a 1.6% increase year-over-year, slightly surpassing consensus estimates [8]. - The company anticipates revenue for the year to be between $7.6 billion and $7.75 billion, with a projected organic growth rate of 2.5% [10]. Shareholder Returns - The company offers a dividend yield of 1.43% with a payout ratio of 16%, complemented by aggressive share buybacks, which are expected to total approximately $375 million, or about 7.6% of market capitalization [5][6]. - Share buybacks reduced the share count by an average of 8.25% in FQ1 2026, with plans to maintain this pace through the end of the year [6]. Market Sentiment and Analyst Ratings - Analysts have mixed responses to SAIC's results, with price targets ranging from $100 to $137, indicating a potential upside of 20% to over 30% from recent lows [13][14]. - The overall analyst rating for SAIC is currently a Hold, with an improving sentiment trend over the past year [10][14]. Strategic Positioning - The company's growth trajectory aligns with the White House's budget proposal, which emphasizes critical segments such as the Navy, Air Force, and Space Development Agency [12]. - SAIC's business is well-positioned to benefit from ongoing government contracts, with a favorable book-to-bill ratio indicating strong future business prospects [10].
ASM share buyback update June 2 – 6, 2025
Globenewswire· 2025-06-09 15:45
Group 1 - ASM International N.V. has conducted share repurchases under its current buyback program, totaling 16,135 shares at an average price of €474.95, amounting to a repurchased value of €7,663,379 [1] - The share buyback program, which commenced on April 30, 2025, has a total budget of €150 million, with 26.1% of the program completed to date [1] - The repurchased shares were acquired on June 2 and June 3, 2025, with specific details on the number of shares and average prices provided [1] Group 2 - ASM International is headquartered in Almere, the Netherlands, and specializes in designing and manufacturing equipment and process solutions for semiconductor device production [2] - The company operates facilities across the United States, Europe, and Asia, and its common stock is traded on the Euronext Amsterdam Stock Exchange under the symbol ASM [2]
Fathom Holdings (FTHM) Is Attractively Priced Despite Fast-paced Momentum
ZACKS· 2025-06-09 13:51
Core Viewpoint - Momentum investing focuses on "buying high and selling higher," contrasting with traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Characteristics - Momentum investing can be risky as stocks may lose momentum when their valuations exceed future growth potential, leading to potential losses for investors [2] - A safer approach involves investing in bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify such opportunities [3] Group 2: Fathom Holdings (FTHM) Analysis - Fathom Holdings (FTHM) has shown significant price movement, with a 52.4% increase over the past four weeks, indicating strong investor interest [4] - The stock has gained 41.2% over the past 12 weeks, demonstrating its ability to deliver positive returns over a longer timeframe [5] - FTHM has a beta of 2.13, suggesting it moves 113% higher than the market in either direction, indicating fast-paced momentum [5] - The stock has a Momentum Score of B, suggesting it is an opportune time to invest [6] - FTHM has received a Zacks Rank 2 (Buy) due to upward revisions in earnings estimates, which typically attract more investor interest [7] - The stock is trading at a low Price-to-Sales ratio of 0.10, indicating it is reasonably valued at present [7] Group 3: Investment Opportunities - FTHM is highlighted as a strong candidate for investment, with potential for further price appreciation [8] - There are additional stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, suggesting a broader opportunity for investors [8] - Zacks offers over 45 Premium Screens tailored to different investing styles, providing various strategies to identify winning stocks [9]
Hologic Climbs 13% in a Month: How Should You Play the Stock?
ZACKS· 2025-06-09 13:45
Core Insights - Hologic (HOLX) has seen a significant share price increase of 13.3% over the past month, outperforming both the industry and broader Medical sector gains of 2.4% and 3.4% respectively, with current prices 23.9% above the 52-week low of $51.90, partly due to the rejection of a private takeover bid from TPG and Blackstone valued at up to $16.7 billion [1][6][9] Performance Comparison - Hologic has outperformed key competitors Exact Sciences (EXAS) and Becton, Dickinson and Company (BDX) during the same timeframe [2] Financial Performance - Following the release of fiscal 2025 second-quarter earnings, Hologic met adjusted EPS expectations but revised its annual outlook due to tariff impacts from China and Costa Rica, funding cuts affecting the Africa business, and a soft capital equipment market [4] Acquisition Interest - The rejected buyout offer from TPG and Blackstone would have valued Hologic's shares between $70 and $72, indicating strong confidence in the company's growth potential [6][7] Clinical Advancements - New data presented at the 2025 American Society of Clinical Oncology Annual Meeting highlighted the significant clinical impact of the Breast Cancer Index (BCI) test, which has been a key growth driver in Hologic's molecular diagnostics business [10][11] Valuation Metrics - Hologic's stock is trading at a price-to-sales (P/S) ratio of 3.40X, below its five-year median of 4.33X and the industry average of 4.16X, indicating an attractive valuation [12][14] Long-Term Growth Prospects - The molecular diagnostics segment is expected to remain a principal revenue driver, with ongoing efforts to expand in the U.S. vaginitis market and a strong pipeline of innovations such as the Envision Mammography Platform [15][16] Analyst Price Target - The average price target for Hologic shares is $68.13, suggesting a potential upside of 8.02% from the recent closing price [17]
Periodic announcement on the acquisition of the Bank‘s own shares and its results (week 5)
Globenewswire· 2025-06-09 06:00
This announcement contains information on transactions of the acquisition of own shares of AB Artea bankas (the Bank) carried during the period specified below under the Bank's own share buy-back programme announced on 30 April 2025. The period during which the acquisition of the Bank's own shares under the programme was carried out – 05.05.2025 – 06.06.2025. <span lang="EN-US" style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-U ...
Elis: Disclosure of trading in own shares occured from June 2 to June 6, 2025
Globenewswire· 2025-06-09 06:00
Disclosure of trading in own shares occurred from June 2 to June 6, 2025 Saint-Cloud, June 9, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from June 2 to June 6, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders' Meeting of May 22, 2025 and announced on March 6, 2025: Aggregated presentation: Issuer nameIssuer code(LEI) Transaction dateISIN CodeDaily tot ...
33/2025・Trifork Group: Weekly report on share buyback
Globenewswire· 2025-06-09 05:41
Core Viewpoint - Trifork Group has initiated a share buyback program, allowing the company to repurchase shares up to a total of DKK 14.92 million (approximately EUR 2 million) from 4 March 2025 to 30 June 2025 [1][2]. Group 1: Share Buyback Program Details - The share buyback program is in accordance with Regulation No. 596/2014 and runs until 30 June 2025 [1]. - As of the latest report, Trifork has repurchased a total of 106,074 shares for a total amount of DKK 9,297,085, with an average purchase price of DKK 87.65 [2]. - Prior to the buyback program, Trifork held 256,329 treasury shares, which represented 1.3% of the share capital [2]. Group 2: Utilization of Repurchased Shares - On specific dates (25 March, 25 April, and 23 May 2025), 4,370 shares from the buyback were used for the Executive Management's monthly fixed salary, transitioning from cash to partial share payment [3]. - Additionally, on 1 April 2025, 19,943 shares were utilized for the RSU plan for Executive Management and certain employees [3]. Group 3: Current Treasury Shares and Outstanding Shares - Following the transactions, Trifork now holds a total of 338,090 treasury shares, which corresponds to 1.7% of the total registered shares [4]. - The total number of registered shares in Trifork is 19,744,899, leading to 19,406,809 outstanding shares after adjusting for treasury shares [4].
Market Valuation Warning Signs: S&P 500 Analysis + Insider Trading Signals
GuruFocus· 2025-06-06 22:27
I'll be glad to share with you know that the market has not been very smooth although it was getting better. It it has been getting better last since last week lots of volatility. Let's review the market valuation that I always do and uh then I'll go to the things that uh we uh that's important to us.Okay, let me share my screen with you here. This is mascaran and uh this is the homepage of guru focus. What you see on your homepage on the homepage might be different from what I see because this page is full ...
Tarkett- AVAILABILITY OF THE RESPONSE DOCUMENT PREPARED BY TARKETT
Globenewswire· 2025-06-06 16:37
THIS DOCUMENT IS AN UNOFFICIAL ENGLISH-LANGUAGE TRANSLATION OF THE PRESS RELEASE REGARDING THE RESPONSE DOCUMENT (NOTE EN RÉPONSE) WHICH WAS FILED WITH THE FRENCH AUTORITÉ DES MARCHÉS FINANCIERS ON JUNE 5, 2025. IN THE EVENT OF ANY DIFFERENCES BETWEEN THIS UNOFFICIAL ENGLISH- LANGUAGE TRANSLATION AND THE OFFICIAL FRENCH RESPONSE DOCUMENT, THE OFFICIAL FRENCH RESPONSE DOCUMENT SHALL PREVAIL. PRESS RELEASE DATED JUNE 6, 2025 AVAILABILITY OF THE RESPONSE DOCUMENT PREPARED BY TARKETT IN THE CONTEXT OF THE PUBLI ...